AU731656B2 - Method of treating heart failure - Google Patents
Method of treating heart failure Download PDFInfo
- Publication number
- AU731656B2 AU731656B2 AU81740/98A AU8174098A AU731656B2 AU 731656 B2 AU731656 B2 AU 731656B2 AU 81740/98 A AU81740/98 A AU 81740/98A AU 8174098 A AU8174098 A AU 8174098A AU 731656 B2 AU731656 B2 AU 731656B2
- Authority
- AU
- Australia
- Prior art keywords
- dose
- adrenergic receptor
- heart failure
- metoprolol
- positive inotropic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5067497P | 1997-06-25 | 1997-06-25 | |
| US60/050674 | 1997-06-25 | ||
| PCT/US1998/013442 WO1998058638A1 (en) | 1997-06-25 | 1998-06-24 | Method of treating heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8174098A AU8174098A (en) | 1999-01-04 |
| AU731656B2 true AU731656B2 (en) | 2001-04-05 |
Family
ID=21966696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU81740/98A Ceased AU731656B2 (en) | 1997-06-25 | 1998-06-24 | Method of treating heart failure |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5998458A (cg-RX-API-DMAC7.html) |
| EP (1) | EP1017376A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002508766A (cg-RX-API-DMAC7.html) |
| AU (1) | AU731656B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2295094A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998058638A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996024358A1 (en) * | 1995-02-10 | 1996-08-15 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
| AR030414A1 (es) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
| SE0002354D0 (sv) * | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
| FI20010233A0 (fi) * | 2001-02-08 | 2001-02-08 | Orion Corp | Menetelmä sydämen vajaatoiminnan hoitoon |
| FI20011464A0 (fi) | 2001-07-04 | 2001-07-04 | Orion Corp | Yhdistelmäterapia sydämen vajaatoiminnan hoitoon |
| US7020521B1 (en) | 2002-11-08 | 2006-03-28 | Pacesetter, Inc. | Methods and apparatus for detecting and/or monitoring heart failure |
| JP2007511487A (ja) | 2003-11-17 | 2007-05-10 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼiv阻害剤の使用 |
| US20060018970A1 (en) * | 2003-12-12 | 2006-01-26 | Myogen, Inc. | Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
| JP2007530566A (ja) * | 2004-03-22 | 2007-11-01 | ミオゲン インコーポレイティッド | (r)−エノキシモンスルホキシドおよびpde−iii媒介疾患の治療におけるその使用 |
| EP1737448A1 (en) * | 2004-03-22 | 2007-01-03 | Myogen, Inc. | (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases |
| US20060292213A1 (en) * | 2004-06-23 | 2006-12-28 | Myogen, Inc. | Enoximone formulations and their use in the treatment of PDE-III mediated diseases |
| CN104644627A (zh) | 2004-09-14 | 2015-05-27 | 科罗拉多大学董事会 | 基于基因靶向使用布新洛尔的治疗方法 |
| CA2610022A1 (en) | 2005-06-06 | 2006-12-14 | Georgetown University | Compositions and methods for lipo modeling |
| WO2007014029A2 (en) * | 2005-07-22 | 2007-02-01 | The Regents Of The University Of Colorado, A Body Corporate | Yin yang 1 as a treatment for cardiac hypertrophy and heart failure |
| WO2011032088A1 (en) | 2009-09-11 | 2011-03-17 | Arca Biopharma, Inc. | Polymorphisms in the pde3a gene |
| CN110520116A (zh) * | 2017-01-03 | 2019-11-29 | 卡尔迪奥克斯尔制药公司 | 供硝酰化合物的给予方法 |
| EP4092013A1 (en) | 2017-06-20 | 2022-11-23 | Imbria Pharmaceuticals, Inc. | Compositions and methods for increasing efficiency of cardiac metabolism |
| US12318382B2 (en) | 2018-10-17 | 2025-06-03 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| EP3976101A4 (en) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION |
| EP4146215A4 (en) * | 2020-05-04 | 2024-05-01 | Imbria Pharmaceuticals, Inc. | DOSING METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE354851B (cg-RX-API-DMAC7.html) * | 1970-02-18 | 1973-03-26 | Haessle Ab | |
| US4405635A (en) * | 1979-06-18 | 1983-09-20 | Merrell Dow Pharmaceuticals Inc. | 4-Aroylimidazol-2-ones and their use as pharmaceuticals |
-
1998
- 1998-06-19 US US09/100,497 patent/US5998458A/en not_active Expired - Lifetime
- 1998-06-24 EP EP19980931687 patent/EP1017376A4/en not_active Ceased
- 1998-06-24 WO PCT/US1998/013442 patent/WO1998058638A1/en not_active Ceased
- 1998-06-24 AU AU81740/98A patent/AU731656B2/en not_active Ceased
- 1998-06-24 JP JP50505699A patent/JP2002508766A/ja active Pending
- 1998-06-24 CA CA002295094A patent/CA2295094A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998058638A1 (en) | 1998-12-30 |
| CA2295094A1 (en) | 1998-12-30 |
| EP1017376A4 (en) | 2002-10-25 |
| EP1017376A1 (en) | 2000-07-12 |
| US5998458A (en) | 1999-12-07 |
| AU8174098A (en) | 1999-01-04 |
| JP2002508766A (ja) | 2002-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5998458A (en) | Method of treating heart failure | |
| JP2022020624A (ja) | 心房拡大又はリモデリングを特徴とする疾患を治療するためのnep阻害剤 | |
| Zimmerman et al. | Vasopressors and inotropes | |
| US9457017B2 (en) | Treatment of heart failure | |
| Chioncel et al. | Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) | |
| WO2022232650A1 (en) | Methods for reducing agt expression | |
| Hoffman | Phosphodiesterase inhibitors | |
| TW202313021A (zh) | 作為強心劑之六氫吡啶脲衍生物 | |
| WO2009066085A1 (en) | Treatment of heart failure with normal ejection fraction | |
| Anderson | Management of beta-adrenergic blocker poisoning | |
| CA2485600C (en) | 5-ht4 receptor antagonists for the treatment of heart failure | |
| Kiriazis et al. | Chronic activation of the low affinity site of β1‐adrenoceptors stimulates haemodynamics but exacerbates pressure‐overload cardiac remodelling | |
| Kikura et al. | New cardiac drugs | |
| Molina et al. | Alcohol does not modulate the augmented acetylcholine-induced vasodilatory response in hemorrhaged rodents | |
| Van Zwieten | Renewed interest in centrally acting antihypertensive drugs | |
| EP3124019B1 (en) | Substance selected among midodrine, a pharmaceutical salt and the active metabolite thereof, for use in the treatment of obstructive cardiopathy | |
| Levy | Support of the perioperative failing heart with preexisting ventricular dysfunction: currently available options | |
| Young et al. | Mg2+ efflux from the isolated perfused rabbit heart is mediated by two states of the β1-adrenergic receptor | |
| Lomivorotov et al. | Perfusion separation challenge | |
| Keskin et al. | Effect of Levosimendan and Milrinone Combination in Chronic Kidney Disease Patients Who Underwent Cardiac Surgery | |
| White et al. | Beneficial effects of prolonged low dose dopamine in hospitalized patients with severe refractory heart failure | |
| CN122055157A (zh) | 降低左心室肥大患者的心血管事件风险的方法 | |
| Fujimoto et al. | Hemodynamic Changes Following Landiolol Initiation in Patients With Critical Illness Who Developed Tachycardia During Dobutamine Infusion: A Retrospective Observational Study | |
| EA047888B1 (ru) | Применение производных пиперидин мочевины в качестве инотропных агентов | |
| Crudu et al. | Renal effects of combination infusion of high dose furosemide and nesiritide in patients with acutely decompensated heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: UNIVERSITY TECHNOLOGY CORPORATION Free format text: FORMER OWNER WAS: MICHAEL R. BRISTOW |
|
| PC | Assignment registered |
Owner name: THE REGENTS OF THE UNIVERSITY OF COLORADO Free format text: FORMER OWNER WAS: UNIVERSITY TECHNOLOGY CORPORATION |